Inflammatory Biomarkers in AD: Implications for Diagnosis

Area of Science:

• Neuroscience
• Biomarker Discovery
• Dementia Research

Background:

• Alzheimer's disease (AD) is the leading cause of dementia, characterized by significant neuronal loss before diagnosis.
• Effective interventions are limited, highlighting the need for early and accurate diagnostic methods.
• Neuroinflammation plays a key role in AD pathogenesis, making inflammatory biomarkers promising diagnostic tools.

Purpose of the Study:

• To review the utility of inflammatory biomarkers for diagnosing Alzheimer's disease.
• To discuss biomarkers detectable via neuroimaging, cerebrospinal fluid (CSF), and peripheral blood.
• To suggest clinical implications and potential for improving patient stratification for early interventions.

Main Methods:

• Review of current literature on inflammatory biomarkers in AD diagnosis.
• Focus on neuroimaging ligands (e.g., TSPO), CSF markers (sTREM2, YKL-40, MCP-1), and peripheral blood markers.
• Analysis of the diagnostic potential and limitations of these biomarkers.

Main Results:

• Neuroimaging, CSF, and peripheral blood inflammatory biomarkers show potential for AD diagnosis.
• Specific biomarkers discussed include TSPO ligands, sTREM2, YKL-40, and MCP-1.
• Evidence suggests these markers can aid in identifying AD, though limitations exist.

Conclusions:

• Inflammatory biomarkers offer a promising avenue for the early diagnosis of Alzheimer's disease.
• Combining these biomarkers with conventional methods like genetic testing and amyloid imaging may enhance patient selection.
• Improved patient stratification can facilitate targeted and timely interventions for AD.